The Administration for Strategic Preparedness and Response (ASPR) has quietly dropped one of the most important funding documents of the year: the 2025–2029 Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Multiyear Budget (MYB). On paper, it is a five‑year budget plan across:
- The Administration for Strategic Preparedness and Response (ASPR)
- The Biomedical Advanced Research and Development Authority (BARDA)
- The Strategic National Stockpile (SNS)
- The National Institutes of Health (NIH)
- The Centers for Disease Control and Prevention (CDC)
- The Food and Drug Administration (FDA)
In practice, it is a heat map of where the federal government believes the next threats are coming from, which platforms it is willing to pay for, and where the gaps will still be even if everything goes according to plan.
The headline numbers: PHEMCE estimates 66.9 billion dollars in total medical countermeasure need across FY 2025–2029 and projects roughly a 33.5 billion dollar shortfall if funding stays flat at FY 2026 levels. That delta gives ASPR and its partners a structured way to prioritize, making it clearer which platforms, manufacturing investments, and stockpile capabilities are most likely to move first as new – or reallocated – dollars come in.
What PHEMCE Is Actually Paying For
The MYB is explicit about what it counts as the medical countermeasure (MCM) enterprise: basic and advanced research, regulatory work, manufacturing, procurement, stockpiling, and replenishment for civilian use in public health emergencies that touch national security. The plan spans traditional CBRN threats (chemical, biological, radiological, nuclear), emerging infectious diseases, and naturally occurring novel pathogens.
A few numbers matter more than the rest:
- About 65 percent of the five‑year need is tied to multi‑threat / threat‑agnostic technologies and emerging infectious diseases, including platform approaches that can be reused across multiple pathogens.
- Pandemic influenza is the single largest threat portfolio, focused on pre‑exposure prophylaxis, better manufacturing, and improved vaccine platforms.
- Broad‑spectrum antimicrobials to address antimicrobial resistance (AMR) sit right behind flu in terms of projected investment.
PHEMCE is essentially saying the center of gravity for the next five years is going to be platform vaccines, broad‑spectrum therapeutics, and flexible diagnostics built to move across multiple respiratory and high‑consequence threats, not one‑off, single‑pathogen bets.
Who Holds the Budget and Where the Gap Sits
The MYB breaks out estimated five‑year needs by HHS division. ASPR–BARDA’s share is about 37.1 billion dollars, ASPR–SNS about 8.2 billion dollars, NIH about 17.1 billion dollars, CDC about 3.2 billion dollars, and FDA about 1.2 billion dollars. FY 2025 figures reflect enacted appropriations, FY 2026 aligns with the President’s Budget, and FY 2027–2029 are based on agency “professional judgment.”
If those later years were held flat at FY 2026 levels, the aggregate shortfall comes out to roughly 33.5 billion dollars against PHEMCE’s identified need. Most of that gap sits inside ASPR’s portfolios:
- BARDA’s advanced development and procurement line would fall more than 27 billion dollars short of the 37.1 billion dollars need if funding never rises above FY 2026 levels.
- SNS would be more than 4 billion dollars below what PHEMCE says is required to transition and replenish products through 2029.
The implication is that even with a detailed five‑year plan, ASPR will still have to prioritize within BARDA and SNS, deciding which platforms advance into late‑stage development and which already‑developed products are actually purchased and sustained in the stockpile.
Stockpile Reality: Thirteen Products, Limited Room
One of the most candid parts of the MYB is the section on product transitions into the Strategic National Stockpile. ASPR reports that two medical countermeasure candidates have already moved from Project BioShield into SNS and expects up to eleven more transitions by FY 2029, for a total of thirteen products. Those include anthrax vaccines and antitoxins, smallpox vaccines and therapeutics, Ebola treatments and vaccines, and radiological / nuclear countermeasures.
ASPR estimates roughly 854 million dollars to support transition and replenishment of these products and is candid that current SNS appropriations do not yet fully match that need. Every new product that moves into SNS brings long‑term lifecycle costs – storage, maintenance, replenishment, and deployment – but it also strengthens the case for sustained investment in operations and manufacturing. The MYB flags the risk that products without a sustainable commercial market could be lost if funding lags, while also giving Congress and HHS a concrete, line-item view of what it would take to lock in those gains.
How NIH, BARDA, CDC, FDA Fit Together
The MYB also lays out a clean division of labor across the federal health ecosystem. NIH continues to carry early‑stage work: basic science, translational research, and early clinical trials to generate candidate MCMs for CBRN and emerging infectious diseases. Once candidates are mature enough, BARDA picks up advanced development, manufacturing scale‑up, and late‑stage clinical trials, positioning products for FDA submission.
FDA, in turn, is responsible for approvals, licensures, clearances, and emergency authorizations, as well as the regulatory science needed to support new technologies and manufacturing approaches. After approval, products intended for stockpiling can move into SNS, which then owns storage, sustainment, and replenishment.
CDC threads through this system by running surveillance and diagnostics that inform which MCMs are needed, for whom, and where; by supporting development and evaluation of countermeasures for high‑consequence pathogens; and by administering the Public Health Emergency Preparedness (PHEP) cooperative agreement that helps states and localities build the capacity to receive and use deployed MCMs.
It is a deliberately sequenced pipeline, with predictable bottlenecks at stockpile transition and in sustaining domestic manufacturing capacity.
What Changes Compared to the Last Plan
This is not the first PHEMCE Multiyear Budget. The prior plan covered 2023–2027 and carried a higher total need. The new MYB trims the overall estimate by about 4 billion dollars while sharpening emphasis on multi‑threat platforms and emerging infectious diseases. It incorporates corrective actions from the 2024 Medical Countermeasure Preparedness Review and reflects recent outbreaks and threat landscape updates, including highly pathogenic avian influenza (H5N1), Ebola, Marburg, and other high‑consequence viruses.
Two shifts stand out:
- Less tolerance for purely pathogen‑specific investments that cannot flex to new threats. The plan consistently favors platforms, broad‑spectrum antivirals, and threat‑agnostic diagnostics.
- More explicit recognition that domestic manufacturing and stockpile sustainment are as much a constraint as scientific discovery. The document flags warm‑base production, surge capacity, and lifecycle funding as core challenges.
Reading The MYB Like a Pipeline Map
The MYB is less of a wish list and more of a pipeline map under budget constraint. It tells you:
- Which threats PHEMCE is still willing to pay real money to address (pandemic flu, AMR, classic CBRN, emerging viral hemorrhagic fevers).
- Which types of technologies it sees as force multipliers (platform vaccines, broad spectrum therapeutics, threat agnostic diagnostics, enabling manufacturing technologies).
- Where the likely choke points will be (BARDA advanced development dollars, SNS transition and replenishment, and the ability of state and local systems to deploy MCMs at scale).
It does not exist in a vacuum; tt sits alongside the emerging leadership and policy posture at CDC and ASPR, including the recent Senate HELP Committee hearing for Dr. Erica Schwartz and Sean Kaufman. For a closer look at how that hearing framed “radical transparency,” scientific integrity, and funding priorities, read our companion piece: CDC and ASPR in the Senate Hot Seat: What the HELP Hearing Reveals About the Next Phase of U.S. Public Health.
For teams that care about medical countermeasure strategy, the value of this document is how the numbers clarify trade-offs across portfolios and agencies, and in how ASPR lays out the choices ahead between many priorities and a finite budget – and, just as importantly, where additional investment could have the biggest impact.
EverGlade is a national advisory firm helping innovators navigate the federal funding ecosystem. We support companies across the funding lifecycle, from early-stage strategy through proposal development, negotiations, and post-award execution, ensuring you win the award and deliver the program.
For additional information on where your capabilities could plug into this evolving landscape, schedule a conversation with our team.
